MedTrace Logo

Initial Combination of Gemigliptin and Metformin on Microbiota Change

NCT02609815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2021-11-22

No results posted yet for this study

Summary

The purpose of this study is to investigate gut microbiota change and glucose lowering effect of initial combination therapy of gemigliptin and metformin compared to glimepiride and metformin in obese patients with type 2 diabetes.

Conditions

Interventions

DRUG

gemigliptin/metformin

zemimet-SR 50/1000 mg x 1 tablet

DRUG

glimepiride/metformin

amaryl-Mex 1/500 mg x 2 tablets

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Tae Jung Oh · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2021-03-15
Completion
2021-03-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609815 on ClinicalTrials.gov